Belinostat
Beleodaq (belinostat) is a small molecule pharmaceutical. Belinostat was first approved as Beleodaq on 2014-07-03. It is used to treat t-cell lymphoma peripheral in the USA. It is known to target histone deacetylase 7, histone deacetylase 1, histone deacetylase 4, histone deacetylase 9, histone deacetylase 2, histone deacetylase 6, histone deacetylase 5, histone deacetylase 3, and histone deacetylase 8.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Beleodaq
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Belinostat
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BELEODAQ | Acrotech Biopharma | N-206256 RX | 2014-07-03 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| beleodaq | New Drug Application | 2025-04-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| t-cell lymphoma peripheral | — | D016411 | — |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J9032 | Injection, belinostat, 10 mg |
Clinical
Clinical Trials
56 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 11 | 6 | 2 | — | — | 18 |
| T-cell lymphoma | D016399 | — | — | 6 | 2 | 2 | — | — | 10 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 5 | 2 | 1 | — | — | 8 |
| T-cell lymphoma peripheral | D016411 | — | — | 4 | 2 | 2 | — | — | 8 |
| Follicular lymphoma | D008224 | — | C82 | 4 | — | 1 | — | — | 5 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 2 | 1 | 1 | — | — | 4 |
| Immunoblastic lymphadenopathy | D007119 | EFO_1001350 | C86.5 | 2 | — | 1 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 11 | 2 | — | — | — | 12 |
| Recurrence | D012008 | — | — | 8 | 4 | — | — | — | 12 |
| Carcinoma | D002277 | — | C80.0 | 4 | 6 | — | — | — | 9 |
| Leukemia | D007938 | — | C95 | 6 | 2 | — | — | — | 8 |
| Syndrome | D013577 | — | — | 6 | 1 | — | — | — | 7 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 5 | 2 | — | — | — | 7 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 5 | 2 | — | — | — | 6 |
| Myeloid leukemia | D007951 | — | C92 | 5 | 2 | — | — | — | 6 |
| Myelodysplastic syndromes | D009190 | — | D46 | 4 | 1 | — | — | — | 5 |
| Preleukemia | D011289 | — | — | 4 | 1 | — | — | — | 5 |
Show 33 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | — | — | 4 | — | — | — | — | 4 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 4 | — | — | — | — | 4 |
| B-cell lymphoma | D016393 | — | — | 4 | — | — | — | — | 4 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 3 | — | — | — | — | 3 |
| Mycoses | D009181 | — | B35-B49 | 3 | — | — | — | — | 3 |
| Hodgkin disease | D006689 | — | C81 | 3 | — | — | — | — | 3 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 3 | — | — | — | — | 3 |
| Mycosis fungoides | D009182 | — | C84.0 | 3 | — | — | — | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | — | — | — | — | 3 |
| Blast crisis | D001752 | — | — | 2 | — | — | — | — | 2 |
Show 27 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Belinostat |
| INN | belinostat |
| Description | Belinostat is a hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. It has a role as an antineoplastic agent and an EC 3.5.1.98 (histone deacetylase) inhibitor. It is a hydroxamic acid, a sulfonamide and an olefinic compound. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: histone deacetylase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO |
Identifiers
| PDB | — |
| CAS-ID | 414864-00-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL408513 |
| ChEBI ID | 61076 |
| PubChem CID | 6918638 |
| DrugBank | DB05015 |
| UNII ID | F4H96P17NZ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HDAC6
HDAC6
HDAC9
HDAC9
HDAC7
HDAC7
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Beleodaq – Spectrum Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,717 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
310 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use